CAS 171500-79-1|Dalbavancin
Introduction：Basic information about CAS 171500-79-1|Dalbavancin, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Dalbavancin | ||
|---|---|---|---|
| CAS Number | 171500-79-1 | Molecular Weight | 1816.692 |
| Density | 1.6±0.1 g/cm3 | Boiling Point | / |
| Molecular Formula | C88H100Cl2N10O28 | Melting Point | / |
| MSDS | / | Flash Point | / |
Names
| Name | dalbavancin |
|---|---|
| Synonym | More Synonyms |
Dalbavancin BiologicalActivity
| Description | Dalbavancin is a lipoglycopeptide antibiotic agent that is active against gram-positive pathogens. |
|---|---|
| Related Catalog | Research Areas >>InfectionSignaling Pathways >>Anti-infection >>Bacterial |
| Target | MIC90: 0.06 μg/mL (Staphylococcus aureus) and 0.25 μg/mL (Bacillus anthracis)[1][2] |
| In Vitro | Dalbavancin is a parenterally administered semisynthetic lipoglycopeptide developed to combat infections caused by resistant gram-positive pathogens. Dalbavancin exhibits potent in vitro bactericidal activity against gram-positive pathogens including S. aureus (MRSA), VISA, and non-VanA strains of VRE. Dalbavancin is developed for the treatment of complicated skin and skin structure infections (cSSSIs), predominantly those caused by MRSA and β-hemolytic streptococci, organisms against which it has shown greater potency than existing glycopeptide therapeutic agents[1][2]. |
| In Vivo | Dalbavancin (15-240 mg/kg; intraperitoneal injection; every 36 h or 72 h; for 14 days; female BALB/c mice) treatment has a survival rate of 80% to 100% of mice with all dose regimens[1]. Animal Model: Female BALB/c mice (6-8 weeks) challenged with Ames strain of B. anthracis[1] Dosage: 15 mg/kg, 30 mg/kg, 60 mg/kg, 120 mg/kg, 240 mg/kg Administration: Intraperitoneal injection; every 36 h or 72 h; for 14 days Result: The efficacy was 80 to 100%, as determined by the rate of survival at 42 days, when treatment was initiated 24 h postchallenge with regimens of 15 to 120 mg/kg every 36 h or 30 to 240 mg/kg every 72 h. |
| References | [1]. Heine HS, et al. Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model. Antimicrob Agents Chemother. 2010 Mar;54(3):991-6. [2]. Bennett JW, et al. Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review. Ther Clin Risk Manag. 2008 Feb;4(1):31-40. |
Chemical & Physical Properties
| Density | 1.6±0.1 g/cm3 |
|---|---|
| Molecular Formula | C88H100Cl2N10O28 |
| Molecular Weight | 1816.692 |
| Exact Mass | 1814.608521 |
| PSA | 572.51000 |
| LogP | 2.94 |
| Index of Refraction | 1.729 |
| InChIKey | KGPGQDLTDHGEGT-SZUNQUCBSA-N |
| SMILES | CNC1C(=O)NC2Cc3ccc(cc3)Oc3cc4cc(c3OC3OC(C(=O)O)C(O)C(O)C3NC(=O)CCCCCCCCC(C)C)Oc3ccc(cc3Cl)C(O)C3NC(=O)C(NC(=O)C4NC(=O)C(NC2=O)c2cc(cc(O)c2Cl)Oc2cc1ccc2O)c1ccc(O)c(c1)-c1c(OC2OC(CO)C(O)C(O)C2O)cc(O)cc1C(C(=O)NCCCN(C)C)NC3=O |
| Storage condition | -20℃ |
Synonyms
| Dalvance |
| Zeven |
| Dalbavancin |
| (1S,2R,19R,22R,33S,36R,39R,51S)-5,31-Dichloro-51-{[3-(dimethylamino)propyl]carbamoyl}-2,25,30,43,48-pentahydroxy-46-(α-D-mannopyranosyloxy)-22-(methylamino)-21,34,37,53,55,58-hexaoxo-7,13,27-triox a-20,35,38,52,54,57-hexaazaundecacyclo[37.14.2.2.2.2.2.1.1.1.0.0]hexahexaconta-3,5,8(64),9,11,14,16,23,25,28(59),29,31,40(56),41,43,45,47,49 ,60,62,65-henicosaen-64-yl 2-deoxy-2-[(10-me |
